Francis Lo, Chief People Officer of Adaptive Biotechnologies (NASDAQ:ADPT), reported the sale of 39,741 shares of Common Stock for a transaction value of approximately $695,000, as disclosed in a SEC Form 4 filing.
Transaction summary
Metric | Value |
|---|---|
Shares sold (direct) | 39,741 |
Transaction value | $695,000 |
Post-transaction shares (direct) | 250,934 |
Post-transaction shares (indirect) | 2,500 |
Post-transaction value (direct ownership) | ~$4.39 million |
Transaction and post-transaction values based on SEC Form 4 weighted average reported price ($17.49).
Key questions
What was the nature of the transaction and how does the derivative context affect interpretation?
The transaction involved exercising 19,521 options and selling 39,741 shares of Common Stock, indicating a liquidity move tied to options-based compensation rather than a reduction in long-term exposure.How did this sale impact Francis Lo’s holdings and ongoing exposure to Adaptive Biotechnologies?
Direct ownership decreased by 13.56% to 250,934 shares, but Lo retains 483,489 stock options, enabling continued potential for equity participation through future conversions.How does this transaction compare to Lo’s prior selling activity and capacity?
The size of the sale is consistent with Lo’s recent pattern, with capacity for future sales reduced proportionally as direct holdings now reflect ~40% of the starting position from the prior year.
Company overview
Metric | Value |
|---|---|
Market capitalization | $2.82 billion |
Revenue (TTM) | $295.41 million |
Net income (TTM) | ($49.68 million) |
1-year price change | 69.07% |
* 1-year price change calculated as of June 4, 2026.
Company snapshot
Core offerings include the immunoSEQ platform for immunosequencing, clonoSEQ for minimal residual disease detection in blood cancers, and T-Detect COVID for confirming past COVID-19 infections. Additional products support vaccine development and translational research.
The company generates revenue through the sale of clinical diagnostics, research tools, and licensing its immune medicine platform, as well as strategic collaborations with pharmaceutical and technology partners.
Primary customers include life science researchers, clinical laboratories, healthcare providers, pharmaceutical partners, and vaccine developers.
Adaptive Biotechnologies leverages a proprietary immune medicine platform to deliver advanced diagnostic and monitoring solutions for cancer, autoimmune disorders, and infectious diseases. Its strategic partnerships enhance its capabilities in both therapeutic development and next-generation diagnostics.
The company’s integrated approach positions it at the forefront of immune-driven precision medicine, supporting both clinical and research applications at scale.
